<DOC>
	<DOCNO>NCT00002254</DOCNO>
	<brief_summary>To assess tolerance toxicity profile deoxy-3'-fluorothymidine ( FLT ) multiple oral dose 16 week . To characterize steady-state pharmacokinetics FLT multiple oral dos . To assess effect FLT immunologic virologic marker HIV infection ( CD4+ lymphocyte count , p24 antigen , viremia ) patient AIDS AIDS relate complex ( ARC ) multiple oral dose 16 week .</brief_summary>
	<brief_title>A Multi-Center , Open-Label , Ascending , Multiple Oral Dose , Safety , Tolerance Pharmacokinetic Study 3'-Deoxy-3'-Fluorothymidine ( FLT ) Patients With Acquired Immune Deficiency Syndrome ( AIDS ) AIDS-Related Complex ( ARC )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine Pneumocystis carinii pneumonia ( PCP ) prophylaxis . Up 14 day systemic therapy minor opportunistic infection candidiasis , mucocutaneous Herpes simplex cutaneous Herpes zoster infection . Patients must follow : AIDS AIDS relate complex ( ARC ) define CDC . Positive antibody HIV determine commercially license ELISA test kit , confirm Western blot analysis . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Symptomatic visceral Kaposi 's sarcoma progression Kaposi 's sarcoma within month prior study entry ( progression define 25 percent increase product bidirectional measurement indicator lesion and/or 25 percent increase number new lesion ) . Concurrent neoplasms Kaposi 's sarcoma basal cell carcinoma skin . Patients malignancy past complete remission 1 year without therapy may enrol . Signs symptoms neuropathy Vibratron 2 score = &gt; 4 either great toe . Concurrent Medication : Excluded : Acute therapy AIDSrelated infection . Systemic maintenance therapy AIDSdefining opportunistic infection . Recombinant erythropoietin . Long term therapy either aspirin probenecid . Concurrent Treatment : Excluded : Blood transfusion per month . Patients follow exclude : Symptomatic visceral Kaposi 's sarcoma progression Kaposi 's sarcoma within month prior study entry . Unwilling sign inform consent patient unwilling follow medical center enrol duration study followup require . History intolerance zidovudine ( AZT ) dose demonstrate AZT related decrease hemoglobin level least 2 g/dl AZT related depression neutrophil least 200 cells/mm3 &lt; 750 cells/mm3 require discontinuation AZT therapy . Diseases condition list Exclusion CoExisting Conditions . Prior Medication : Excluded : Antiretroviral agent within 14 day study entry . Immunomodulating agent corticosteroid within 30 day prior study entry . Treatment acute Pneumocystis carinii pneumonia within 2 week prior study entry . Prior Treatment : Excluded : Blood transfusion within 7 day prior study entry . Radiation therapy Kaposi 's sarcoma within 30 day prior study entry . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1991</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>